Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions
Interventions
Observation group (Group A: ECOG=1
or weight 60kg, study participants received senaparib 100mg):None
Sponsors
West China Second University Hospital of Sichuan University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Signed informed consent and voluntary enrollment in the study; 2. Histologically or cytologically confirmed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer; 3. Age >=18 years; 4. Investigator determines the patient is eligible for senaparib treatment; 5. For participants of childbearing potential, effective contraception must be used during the study and for 90 days after the last dose of senaparib.
Exclusion criteria
Exclusion criteria: 1. Confirmed pregnancy or lactation in female patients; 2. Participating in any study with interventions outside of routine clinical practice; 3. Any other condition which, in the investigator's judgment, makes the patient unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety Outcomes (including adverse event type, incidence, grading, severity, and relationship to drug); | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Treatment (DOT);Progression-Free Survival (PFS);Overall Survival (OS); | — |
Countries
China
Contacts
Public ContactLi Qingli
West China Second University Hospital of Sichuan University
Outcome results
None listed